Life sciences company Avacta Group revealed on Monday that its clinical stage oncology biotech division Avacta Therapeutics Avacta Therapeutics (AIM: AVCT) has entered into a strategic collaboration with technology company Tempus AI Inc (Nasdaq: TEM) to advance artificial intelligence applications in drug development for oncology.
This partnership grants Avacta access to Tempus' extensive multimodal datasets, which include primary tumour samples and clinical data from over 200,000 cancer patients.
The collaboration aims to deepen the understanding of the tumour microenvironment and fibroblast activation protein (FAP) activity, foundational elements of Avacta's pre|CISION technology. This platform targets potent anti-tumour payloads directly to tumours, minimising exposure to healthy tissues.
Additionally, Avacta has expanded its pre|CISION platform with two new preclinical programs: AVA6103, a peptide drug conjugate using exatecan, and AVA7100, a first-in-class Affimer drug conjugate designed for cancers with varying FAP expression. These programs underscore the platform's versatility in addressing diverse cancer indications.
The collaboration will leverage Tempus's analytical expertise to refine patient population identification for Avacta's clinical programs. Avacta's lead program, AVA6000, a peptide drug conjugate of doxorubicin, is currently in Phase 1 trials, showing improved safety and preliminary clinical activity compared to standard doxorubicin.
Avacta Group is committed to enhancing healthcare outcomes through targeted cancer treatments and diagnostics, utilising its proprietary pre|CISION technology to develop innovative cancer therapies.
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Avacta Group partners with Tempus to enhance AI-driven oncology drug development
PharmaLogic opens new radiopharmaceutical facility in Salt Lake City
Astellas Pharma's VYLOY receives US FDA approval
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Elysium Health launches VISION for visual performance and eye health
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Innovent Biologic meets primary endpoint in picankibart phase 2 study